Dopamine reuptake inhibitor related to modafinil being developed for stimulant use disorder
 ;templatestyles src="Infobox drug/styles.css"/ ;
RDS03-94, or RDS3-094, is an atypical dopamine reuptake inhibitor that was derived from the wakefulness-promoting agent modafinil.
It has substantially higher affinity and potency in terms of dopamine transporter (DAT) inhibition than modafinil (Ki = 39.4nM vs. 8,160nM) whilst retaining the atypical DAT blocker profile of modafinil. However, RDS03-94 also has high affinity for the sigma σ1 receptor (Ki = 2.19nM).
RDS03-94 shows some reversal of tetrabenazine-induced motivational deficits in animals and hence may have the capacity to produce pro-motivational effects. However, it appears to be less effective than certain other related agents, like JJC8-088.
RDS03-94 is under development for the treatment of psychostimulant use disorder. The drug was first described in the scientific literature in 2020.
References.
 ;templatestyles src="Reflist/styles.css" / ;